<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition
Tania Moujaber(The University of Sydney), Anna DeFazio(The University of Sydney), Casina W.S. Kan(Roche (Switzerland)), Alexander Dobrovic(The University of Melbourne), David D.L. Bowtell(The University of Melbourne), Sivatharsny Srirangan(Westmead Institute for Medical Research), Ann‐Marie Patch(QIMR Berghofer Medical Research Institute), Catherine A.B. Saunders(Roche (Switzerland)), John V. Pearson(The University of Queensland), Sean M. Grimmond(Center for Genomic Science), Gerard Wain(Westmead Hospital), Catherine J. Kennedy(The University of Sydney), Sián Fereday(Peter MacCallum Cancer Centre), Yoke-Eng Chiew(The University of Sydney), Bo Gao(Sun Yat-sen University), Paul R. Harnett(The University of Sydney), Rosemary L. Balleine(The University of Sydney), Dariush Etemadmoghadam(Peter MacCallum Cancer Centre), Nadia Traficante(The University of Melbourne), Russell Hogg(Westmead Hospital), Nicola Waddell(QIMR Berghofer Medical Research Institute)
Cited by 40
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Whole genomes redefine the mutational landscape of pancreatic cancer
|Nature|2015|2.7k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k